NOX 14.3% 8.0¢ noxopharm limited

Ann: New Independent Trial Data Supports Potential of Veyonda, page-18

  1. RBx
    643 Posts.
    lightbulb Created with Sketch. 1002
    WARMTH patients only received a median of three cycles because Lu-PSMA was no longer effective after that point.

    The median of 5 cycles in LuPIN is a big plus for NOX66: the combination of NOX66 and Lu-PSMA worked for a longer time, which is good for patients; and Novartis would be able to charge their fees for additional cycles, which would be good for Novartis.
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
8.0¢
Change
0.010(14.3%)
Mkt cap ! $23.37M
Open High Low Value Volume
7.0¢ 8.0¢ 7.0¢ $4.207K 56.02K

Buyers (Bids)

No. Vol. Price($)
1 118527 7.5¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 4999 1
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.